Infigratinib is an kinase inhibitor in development for the treatment of achondroplasia and hypochondroplasia. [1] [4] [5] Infigratinib targets the fibroblast growth factor receptors FGFR1, …

2024年9月17日 · – BridgeBio will leverage the benefits of Breakthrough Therapy Designation to expedite the development and regulatory review of infigratinib in the United States and if …

UPDATE: On May 16, 2024, the FDA announced the final withdrawal of the approval of infigratinib (Truseltiq) for previously treated, unresectable locally advanced or metastatic …

Infigratinib is an FGFR inhibitor used to treat locally advanced or metastatic cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) rearrangement.

Infigratinib is used to treat cholangiocarcinoma (bile duct cancer) that has spread or cannot be removed by surgery. It is used in patients who have already tried cancer treatment before and …

2024年6月12日 · Infigratinib is used to treat bile duct cancer that has an abnormal "FGFR2" gene and has spread to other parts of the body (metastatic) after other treatment, and cannot be …

Find patient medical information for infigratinib oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.

2023年12月20日 · Infigratinib is a prescription medication indicated for the treatment of adults with previously treated, unresectable locally advanced, or metastatic cholangiocarcinoma with a …

Infigratinib This information from Lexicomp explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare …

2022年12月12日 · What is this drug used for? It is used to treat bile duct cancer. What do I need to tell my doctor BEFORE I take this drug? If you are allergic to this drug; any part of this drug; …